Clopidogrel was the first P2Y12 inhibitor tested against aspirin in the context of monotherapy in patients with CAD, and the interest in clopidogrel monotherapy was further increased after the recognition that its administration is associated with a better risk–benefit profile compared to aspirin in patients at high risk for bleeding, such as those receiving oral anticoagulants [91]. Here, P2RY12 is linked to coronary artery disorder.